Managing Ischemic Stroke in Patients Already on Anticoagulation for Atrial Fibrillation: A Nationwide Practice Survey.

[1]  S. Connolly,et al.  Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis. , 2019, Stroke.

[2]  K. Furie,et al.  Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. , 2019, Stroke.

[3]  Hugh Calkins,et al.  Correction to: 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Circulation.

[4]  R. Arbel,et al.  Effectiveness and Safety of Off-Label Dose-Reduced Direct Oral Anticoagulants in Atrial Fibrillation. , 2019, The American journal of medicine.

[5]  D. Werring,et al.  Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation , 2019, Annals of neurology.

[6]  G. Lip,et al.  Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients , 2018, Stroke.

[7]  J. Grotta,et al.  To Treat or Not to Treat?: Exploring Factors Influencing Intravenous Thrombolysis Treatment Decisions for Minor Stroke , 2018, Stroke.

[8]  K. Lawson,et al.  Direct oral anticoagulant prescription trends, switching patterns, and adherence in Texas Medicaid. , 2018, American Journal of Managed Care.

[9]  T. Olsen,et al.  Risk of Ischemic and Hemorrhagic Strokes in Occult and Manifest Cancers , 2018, Stroke.

[10]  K. Kario,et al.  Two-Year Outcomes of Anticoagulation for Acute Ischemic Stroke With Nonvalvular Atrial Fibrillation　- SAMURAI-NVAF Study. , 2018, Circulation journal : official journal of the Japanese Circulation Society.

[11]  L. Mbuagbaw,et al.  Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies , 2018, European Journal of Epidemiology.

[12]  M. Hill,et al.  Temporal Trends in the Use and Comparative Effectiveness of Direct Oral Anticoagulant Agents Versus Warfarin for Nonvalvular Atrial Fibrillation: A Canadian Population‐Based Study , 2017, Journal of the American Heart Association.

[13]  M. Alberts,et al.  Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack , 2017, Stroke.

[14]  Cryptogenic Stroke and Nonstenosing Intracranial Calcified Atherosclerosis. , 2017, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[15]  P. Michel,et al.  Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta-analysis of randomized controlled trials , 2017, International journal of stroke : official journal of the International Stroke Society.

[16]  J. Hallas,et al.  Clinical events preceding switching and discontinuation of oral anticoagulant treatment in patients with atrial fibrillation , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[17]  P. Noseworthy,et al.  Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. , 2016, Chest.

[18]  J. Broderick,et al.  The National Institutes of Health StrokeNet: A User's Guide. , 2016, Stroke.

[19]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[20]  V. Chair,et al.  Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. , 2014, Stroke.

[21]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[22]  G. Lip,et al.  Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-Analysis of the Literature , 2012, Circulation.

[23]  V. Menon,et al.  Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. , 2012, Archives of internal medicine.

[24]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[25]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[26]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[27]  Robert D. Brown,et al.  Central nervous system manifestations of cardiac myxoma. , 2007, Archives of neurology.

[28]  M. Streiff,et al.  Nonbacterial thrombotic endocarditis in cancer patients: pathogenesis, diagnosis, and treatment. , 2007, The oncologist.

[29]  Nicola J Cooper,et al.  Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. , 2006, Archives of internal medicine.

[30]  Jan Claassen,et al.  Treatment of status epilepticus: a survey of neurologists , 2003, Journal of the Neurological Sciences.

[31]  P A Wolf,et al.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. , 1998, The American journal of cardiology.